T. Rowe Price Associates
BLTE

T. Rowe Price Associates’s Belite Bio BLTE Stock Holding History

T. Rowe Price Associates’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Sell
105,859
-175,946
-62% -$27M ﹤0.01% 1201
2026
Q1 		$44.9M Buy
+281,805
New +$47.4M 0.01% 802

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's BLTE Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Belite Bio (BLTE) stake by 62% in Q2 2026, selling an estimated $27M and leaving 105,859 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

T. Rowe Price Associates first reported a position in BLTE in Q1 2026 and has held it in 2 quarters since. The position peaked at $44.9M in Q1 2026. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • T. Rowe Price Associates held 105,859 shares of Belite Bio worth $16.3M as of Q2 2026.
  • T. Rowe Price Associates sold 175,946 Belite Bio shares in Q2 2026, an estimated $27M.
  • Belite Bio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1201 holding.
  • T. Rowe Price Associates first reported a position in Belite Bio in Q1 2026 and has held it in 2 quarters since.
  • T. Rowe Price Associates's Belite Bio position peaked at $44.9M in Q1 2026.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.